Immunocore Holdings plc
Immunocore Holdings plc, a pioneering biotechnology company headquartered in Great Britain, is at the forefront of developing innovative T cell receptor (TCR) therapies for cancer and other serious diseases. Founded in 2008, Immunocore has made significant strides in the biopharmaceutical industry, particularly with its proprietary ImmTAC platform, which harnesses the power of T cells to target and destroy cancer cells. With a strong operational presence in Europe and North America, Immunocore has established itself as a leader in the field of immuno-oncology. The company’s flagship product, tebentafusp, has garnered attention for its unique mechanism of action and has received regulatory approvals for treating metastatic uveal melanoma. Recognised for its commitment to advancing cancer treatment, Immunocore continues to push the boundaries of science, positioning itself as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Immunocore Holdings plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immunocore Holdings plc's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immunocore Holdings plc's reported carbon emissions
Immunocore Holdings plc, headquartered in Great Britain, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As there are no emissions data or reduction initiatives available, it is unclear how Immunocore Holdings plc aligns with industry standards for climate action. The absence of specific targets or commitments may reflect a broader trend within the biotechnology sector, where companies are increasingly being called upon to disclose their environmental impact and set ambitious sustainability goals. In summary, without available emissions data or reduction initiatives, Immunocore Holdings plc's current climate commitments remain unspecified, highlighting an opportunity for the company to enhance its environmental strategy and transparency in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Immunocore Holdings plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
